Prostatype Genomics AB
STO:PROGEN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.7
68.5758
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PROGEN stock under the Base Case scenario is 6.83 SEK. Compared to the current market price of 9.7 SEK, Prostatype Genomics AB is Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Prostatype Genomics AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PROGEN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Prostatype Genomics AB
Balance Sheet Decomposition
Prostatype Genomics AB
Current Assets | 3.2m |
Cash & Short-Term Investments | 1.8m |
Receivables | 1.2m |
Other Current Assets | 200k |
Non-Current Assets | 29.1m |
Long-Term Investments | 81k |
PP&E | 53k |
Intangibles | 29m |
Other Non-Current Assets | -1k |
Current Liabilities | 19m |
Other Current Liabilities | 19m |
Earnings Waterfall
Prostatype Genomics AB
Revenue
|
1m
SEK
|
Cost of Revenue
|
3.1m
SEK
|
Gross Profit
|
4.1m
SEK
|
Operating Expenses
|
-42.2m
SEK
|
Operating Income
|
-38.1m
SEK
|
Other Expenses
|
-2.4m
SEK
|
Net Income
|
-40.5m
SEK
|
Free Cash Flow Analysis
Prostatype Genomics AB
SEK | |
Free Cash Flow | SEK |
PROGEN Profitability Score
Profitability Due Diligence
Prostatype Genomics AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Prostatype Genomics AB's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
PROGEN Solvency Score
Solvency Due Diligence
Prostatype Genomics AB's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Prostatype Genomics AB's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PROGEN Price Targets Summary
Prostatype Genomics AB
Dividends
Current shareholder yield for PROGEN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. The company is headquartered in Solna, Stockholm. The company went IPO on 2020-11-03. The firm's business model and concept is to manufacture, market and sell the Prostatype Test System as one prognostic package consisting of the Prostatype RTqPCR kit, the patient database and the evaluation software and accessories P-score. The test is supposed to check the aggressiveness of the prostate cancer in order to help clinicians and patients to make correct treatment decisions. Prostatype analyzes the gene expression in cancer cells extracted from prostate tissue and gives, in combination with an advanced algorithm and data analysis, decision support for optimal treatment of individual patients once prostate cancer has been confirmed.
Contact
IPO
Employees
Officers
The intrinsic value of one PROGEN stock under the Base Case scenario is 6.83 SEK.
Compared to the current market price of 9.7 SEK, Prostatype Genomics AB is Overvalued by 30%.